Comparison of intensive and low-dose atorvastatin therapy in the reduction of carotid intimal-medial thickness in patients with coronary heart disease

被引:62
作者
Yu, Cheuk-Man [1 ]
Zhang, Qing
Lam, Linda
Lin, Hong
Kong, Shun-Ling
Chan, Wilson
Wing-Hong Fung, Jeffrey
Fung, Hong
Cheng, Kenny K. K.
Chan, Iris Hiu-Shuen
Lee, Stephen Wai-Luen
Sanderson, John E.
Lam, Christopher Wai-Kei
机构
[1] Chinese Univ Hong Kong, Prince Wales Hosp, Div Cardiol, SH HO Cardiovasc & Stroke Ctr,Dept Med & Therapeu, Shatin, Hong Kong, Peoples R China
[2] Queen Mary Hosp, Dept Med, Hong Kong, Hong Kong, Peoples R China
[3] City Gen Hosp, Dept Cardiol, Stoke On Trent ST4 6QG, Staffs, England
[4] Univ Birmingham, Sch Med, Dept Cardiovasc Med, Birmingham, W Midlands, England
[5] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Chem Pathol, Hong Kong, Hong Kong, Peoples R China
关键词
D O I
10.1136/hrt.2006.102848
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Intensive statin therapy has been shown to improve prognosis in patients with coronary heart disease (CHD). It is unknown whether such benefit is mediated through the reduction of atherosclerotic plaque burden. Aim: To examine the efficacy of high-dose atorvastatin in the reduction of carotid intimal - medial thickness (IMT) and inflammatory markers in patients with CHD. Design: Randomised trial. Setting: Single centre. Patients: 112 patients with angiographic evidence of CHD. Interventions: A high dose (80 mg daily) or low dose (10 mg daily) of atorvastatin was given for 26 weeks. Main outcome measures: Carotid IMT, C-reactive protein (CRP) and proinflammatory cytokine levels were assessed before and after therapy. Results: The carotid IMT was reduced significantly in the high-dose group (left: mean (SD), 1.24 (0.48) vs 1.15 (0.35) mm, p = 0.02; right: 1.12 (0.41) vs 1.01 (0.26) mm, p = 0.01), but was unchanged in the lowdose group (left: 1.25 (0.55) vs 1.20 (0.51) mm, p = NS; right: 1.18 (0.54) vs 1.15 (0.41) mm, p = NS). The CRP levels were reduced only in the high-dose group (from 3.92 (6.59) to 1.35 (1.83) mg/l, p = 0.01), but not in the low-dose group (from 2.25 (1.84) to 3.36 (6.15) mg/l, p = NS). A modest correlation was observed between the changes in carotid IMT and CRP (r = 0.21, p = 0.03). Conclusions: In patients with CHD, intensive atorvastatin therapy results in regression of carotid atherosclerotic disease, which is associated with reduction in CRP levels. On the other hand, a low- dose regimen only prevents progression of the disease.
引用
收藏
页码:933 / 939
页数:7
相关论文
共 33 条
[1]   Interaction between chemokines and oxidative stress:: Possible pathogenic role in acute coronary syndromes [J].
Aukrust, P ;
Berge, RK ;
Ueland, T ;
Aaser, E ;
Damås, JK ;
Wikeby, L ;
Brunsvig, A ;
Müller, F ;
Forfang, K ;
Froland, SS ;
Gullestad, L .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2001, 37 (02) :485-491
[2]  
Balbarini A, 2000, ANGIOLOGY, V51, P269
[3]   Elevated levels of interleukin-6 in unstable angina [J].
Biasucci, LM ;
Vitelli, A ;
Liuzzo, G ;
Altamura, S ;
Caligiuri, G ;
Monaco, C ;
Rebuzzi, AG ;
Ciliberto, G ;
Maseri, A .
CIRCULATION, 1996, 94 (05) :874-877
[4]   Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina [J].
Blankenberg, S ;
Tiret, L ;
Bickel, C ;
Peetz, D ;
Cambien, F ;
Meyer, J ;
Rupprecht, HJ .
CIRCULATION, 2002, 106 (01) :24-30
[5]   Final outcome results of the multicenter isradipine diuretic atherosclerosis study (MIDAS) - A randomized controlled trial [J].
Borhani, NO ;
Mercuri, M ;
Borhani, PA ;
Buckalew, VM ;
CanossaTerris, M ;
Carr, AA ;
Kappagoda, T ;
Rocco, MV ;
Schnaper, HW ;
Sowers, JR ;
Bond, MG .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 276 (10) :785-791
[6]   Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease [J].
Brown, BG ;
Zhao, XQ ;
Chait, A ;
Fisher, LD ;
Cheung, MC ;
Morse, JS ;
Dowdy, AA ;
Marino, EK ;
Bolson, EL ;
Alaupovic, P ;
Frohlich, J ;
Albers, JJ ;
Serafini, L ;
Huss-Frechette, E ;
Wang, S ;
DeAngelis, D ;
Dodek, A .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (22) :1583-1592
[7]   Intensive versus moderate lipid lowering with statins after acute coronary syndromes [J].
Cannon, CP ;
Braunwald, E ;
McCabe, CH ;
Rader, DJ ;
Rouleau, JL ;
Belder, R ;
Joyal, SV ;
Hill, KA ;
Pfeffer, MA ;
Skene, AM .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (15) :1495-1504
[8]  
Chambless LE, 2000, AM J EPIDEMIOL, V151, P478
[9]   Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) [J].
Cleeman, JI ;
Grundy, SM ;
Becker, D ;
Clark, LT ;
Cooper, RS ;
Denke, MA ;
Howard, WJ ;
Hunninghake, DB ;
Illingworth, DR ;
Luepker, RV ;
McBride, P ;
McKenney, JM ;
Pasternak, RC ;
Stone, NJ ;
Van Horn, L ;
Brewer, HB ;
Ernst, ND ;
Gordon, D ;
Levy, D ;
Rifkind, B ;
Rossouw, JE ;
Savage, P ;
Haffner, SM ;
Orloff, DG ;
Proschan, MA ;
Schwartz, JS ;
Sempos, CT ;
Shero, ST ;
Murray, EZ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19) :2486-2497
[10]   Effects of lipid-lowering by simvastatin on human atherosclerotic lesions - A longitudinal study by high-resolution, noninvasive magnetic resonance imaging [J].
Corti, R ;
Fayad, ZA ;
Fuster, V ;
Worthley, SG ;
Helft, G ;
Chesebro, J ;
Mercuri, M ;
Badimon, JJ .
CIRCULATION, 2001, 104 (03) :249-252